Pharmaceuticals policy

ePharmacy Market Size Worth $169.3 Billion By 2028 | CAGR: 18.4%: Grand View Research, Inc.

Retrieved on: 
星期一, 九月 6, 2021
Retailing, Retailers, Health, Online pharmacies, Pharmacy, Pharmaceuticals policy, Amazon, E-commerce, COVID-19 pandemic

In addition, benefits, such as affordability, convenience, and ease in the availability of medicines, are boosting the adoption of these platforms.

Key Points: 
  • In addition, benefits, such as affordability, convenience, and ease in the availability of medicines, are boosting the adoption of these platforms.
  • Read 150 page market research report, " ePharmacy Market Size, Share & Trends Analysis Report By Region (Middle East & Africa, North America, Europe, Asia Pacific, Latin America), And Segment Forecasts, 2021 - 2028 ", by Grand View Research.
  • As per the article published by Economic Times, in July 2021, the number of households utilizing ePharmacy services grew 2.5 times to 9.0 million during the pandemic.
  • Grand View Research, has segmented the global ePharmacy market on the basis of region:

ePharmacy Market Size Worth $169.3 Billion By 2028 | CAGR: 18.4%: Grand View Research, Inc.

Retrieved on: 
星期一, 九月 6, 2021
Retailing, Retailers, Health, Online pharmacies, Pharmacy, Pharmaceuticals policy, Amazon, E-commerce, COVID-19 pandemic

In addition, benefits, such as affordability, convenience, and ease in the availability of medicines, are boosting the adoption of these platforms.

Key Points: 
  • In addition, benefits, such as affordability, convenience, and ease in the availability of medicines, are boosting the adoption of these platforms.
  • Read 150 page market research report, " ePharmacy Market Size, Share & Trends Analysis Report By Region (Middle East & Africa, North America, Europe, Asia Pacific, Latin America), And Segment Forecasts, 2021 - 2028 ", by Grand View Research.
  • As per the article published by Economic Times, in July 2021, the number of households utilizing ePharmacy services grew 2.5 times to 9.0 million during the pandemic.
  • Grand View Research, has segmented the global ePharmacy market on the basis of region:

The National Medical Products Administration (NMPA) issues product license for Abiraterone acetate 250 mg, Bioequivalance study conducted in India by Accutest Research Laboratories (I) Pvt. Ltd., one of the Top Indian CRO

Retrieved on: 
星期一, 九月 6, 2021
Health care, Health, Pharmaceutical industry, Pharmaceuticals policy, Abiraterone acetate, Antiestrogens, Pyridines, Contract research organization, Food and Drug Administration, Drugs Controller General of India, Pharmaceutical industry in India

BEIJING and MUMBAI, India, Sept. 6, 2021 /PRNewswire/ -- National Medical Products Administration (NMPA) China, announces the approval of Abiraterone acetate 250mg of Qilu Pharmaceuticals for marketing purpose.

Key Points: 
  • BEIJING and MUMBAI, India, Sept. 6, 2021 /PRNewswire/ -- National Medical Products Administration (NMPA) China, announces the approval of Abiraterone acetate 250mg of Qilu Pharmaceuticals for marketing purpose.
  • Applicable Bioequivalance studies for marketing authorization were conducted at Accutest Research Laboratories (I) Pvt.
  • Accutest is a Contract Research Organization (CRO) offering full range of services based in India.
  • An official from Clinical affairs department of Qilu Pharma said, "Thanks to Accutest Research Laboratories, we have successfully achieved our goal in the advance for the Abiraterone acetate projects.

Dr. Reddy’s Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)

Retrieved on: 
星期六, 九月 4, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Health sciences, Health care, Health, NIFTY 50, Pharmaceuticals policy, Dr. Reddy's Laboratories, Pharmacy, Forward-looking statement, Reddy, Pharmaceutical industry in China, Eisai, Cutaneous T cell lymphoma

Further, Dr. Reddys will receive certain sales-based milestones and tiered earn-out payments.

Key Points: 
  • Further, Dr. Reddys will receive certain sales-based milestones and tiered earn-out payments.
  • In March 2016, Dr. Reddys had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co. Ltd.
    Erez Israeli, Chief Executive Officer, Dr. Reddys, said: Addressing unmet patient needs in oncology remains a prime focus area for us.
  • E7777 has significant potential as an important component of systemic therapy for CTCL and other cancers.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

TFF Pharmaceuticals to Hold Second Quarter 2021 Financial and Business Results Conference Call on August 12, 2021

Retrieved on: 
星期三, 八月 4, 2021
Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Health care

Management will host a conference call to discuss the financial results and provide an update on recent corporate and clinical developments at4:30 PM EDT.

Key Points: 
  • Management will host a conference call to discuss the financial results and provide an update on recent corporate and clinical developments at4:30 PM EDT.
  • The Company will host a conference call on Thursday, August 12, 2021, at 4:30 PM EDT to review the clinical, corporate and financial highlights.
  • Please access the Company's website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.
  • TFF Pharmaceuticals, Inc.is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform.

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis

Retrieved on: 
星期三, 八月 4, 2021
Health sciences, Health, Food and Drug Administration, Life sciences, Pharmaceuticals policy, Drug discovery, Biotechnology law, Orphan drug, Orphan Drug Act, Clinical trial, Food and Drug Administration Safety and Innovation Act, Breakthrough therapy

The FDA evaluated the research data licensed from KU in the ODD application that ultimately served as the foundation to allow the FDA to grant the designation.

Key Points: 
  • The FDA evaluated the research data licensed from KU in the ODD application that ultimately served as the foundation to allow the FDA to grant the designation.
  • The Orphan Drug Act grants special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor.
  • The FDA grants orphan status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.
  • PharmaTher is currently initiating an FDA approved phase 2 clinical study with ketamine to treat Parkinsons disease and is developing a novel microneedle patch for the intradermal delivery of psychedelics.

MMS Director Appointed to the Pharmacovigilance Council for the Indian Society of Clinical Research

Retrieved on: 
星期三, 八月 4, 2021
Health, Other Science, General Health, Research, Pharmaceutical, Science, Pharmaceuticals policy, Health, Clinical research, Clinical trials, Health care quality, Pharmacovigilance, Drug safety

MMS Holdings Inc. (MMS) an award-winning, data-focused CRO announced today that Arunima Sen, MD, Director of Pharmacovigilance and Medical Writing (India), has been appointed to the Indian Society of Clinical Researchs Pharmacovigilance Council.

Key Points: 
  • MMS Holdings Inc. (MMS) an award-winning, data-focused CRO announced today that Arunima Sen, MD, Director of Pharmacovigilance and Medical Writing (India), has been appointed to the Indian Society of Clinical Researchs Pharmacovigilance Council.
  • The Indian Society of Clinical Research (ISCR) brings together those engaged in clinical research activities in India to build awareness of clinical research as a specialty, maintain the highest standards of quality and ethics, and build its growth in the country.
  • The ISCR Pharmacovigilance Council aims to:
    I would like to personally congratulate Arunima for being selected to be part of this esteemed council, said Michelle Gayari, Executive Vice President, Global Operational Excellence and Innovation, MMS.
  • This appointment underscores the excellence and strength of our continued leadership in pharmacovigilance and drug safety within the pharmaceutical industry.

ArisGlobal Highlights R&D Innovation, Digital Transformation, and AI at Breakthrough2021

Retrieved on: 
星期三, 八月 4, 2021
Articles, Pharmaceuticals policy, Health, Clinical research, Clinical trials, Health care quality, Pharmacovigilance, Digital transformation

MIAMI, Aug. 4, 2021 /PRNewswire/ -- ArisGlobal, the leading provider of life sciences software that automates core drug development functions for over 300 life sciences companies, today announced its Breakthrough2021 Conference. Held virtually on September 21-22, Breakthrough2021 will feature key leaders across the life sciences industry and engage them in critical discussions related to R&D innovation, digital health, patient safety, enterprise automation, and a variety of other topics.

Key Points: 
  • A few keynote speakers and sessions include:
    Sean Duffy, CEO at Omada Health, with a special keynote address on Digital Health and the future of the industry.
  • Beena Wood, Vice President of Safety and Medical Affairs at ArisGlobal, will address the continual evolution of safety within life sciences and what innovations are required to keep pace with industry digital transformation.
  • ArisGlobal transforms the way today's most successful Life Sciences companies develop breakthroughs and bring new products to market.
  • In 2021, Frost & Sullivan recognized ArisGlobal with the Customer Value Leadership Award for Clinical Development and Pharmacovigilance Software.

ArisGlobal Highlights R&D Innovation, Digital Transformation, and AI at Breakthrough2021

Retrieved on: 
星期三, 八月 4, 2021
Articles, Pharmaceuticals policy, Health, Clinical research, Clinical trials, Health care quality, Pharmacovigilance, Digital transformation

MIAMI, Aug. 4, 2021 /PRNewswire/ -- ArisGlobal, the leading provider of life sciences software that automates core drug development functions for over 300 life sciences companies, today announced its Breakthrough2021 Conference. Held virtually on September 21-22, Breakthrough2021 will feature key leaders across the life sciences industry and engage them in critical discussions related to R&D innovation, digital health, patient safety, enterprise automation, and a variety of other topics.

Key Points: 
  • A few keynote speakers and sessions include:
    Sean Duffy, CEO at Omada Health, with a special keynote address on Digital Health and the future of the industry.
  • Beena Wood, Vice President of Safety and Medical Affairs at ArisGlobal, will address the continual evolution of safety within life sciences and what innovations are required to keep pace with industry digital transformation.
  • ArisGlobal transforms the way today's most successful Life Sciences companies develop breakthroughs and bring new products to market.
  • In 2021, Frost & Sullivan recognized ArisGlobal with the Customer Value Leadership Award for Clinical Development and Pharmacovigilance Software.

Eton Pharmaceuticals to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021

Retrieved on: 
星期二, 八月 3, 2021
Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Health care, Pharmacy

DEER PARK, Ill., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2021 financial and operating results on Monday, August 16, 2021.

Key Points: 
  • DEER PARK, Ill., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2021 financial and operating results on Monday, August 16, 2021.
  • Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m.
  • The conference call can be accessed by dialing 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 2454465.
  • Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.